These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19366851)

  • 1. Pretreatment insulin-like growth factor-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease.
    Biermasz NR; Wassenaar MJ; van der Klaauw AA; Pereira AM; Smit JW; Roelfsema F; Wolterbeek R; Kroon HM; Kloppenburg M; Romijn JA
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2374-9. PubMed ID: 19366851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN).
    Claessen KM; Kloppenburg M; Kroon HM; Romijn JA; Pereira AM; Biermasz NR
    Growth Horm IGF Res; 2013 Oct; 23(5):159-64. PubMed ID: 23810124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly.
    Wassenaar MJ; Biermasz NR; Pereira AM; van der Klaauw AA; Smit JW; Roelfsema F; van der Straaten T; Cazemier M; Hommes DW; Kroon HM; Kloppenburg M; Guchelaar HJ; Romijn JA
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4671-8. PubMed ID: 19864451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case-control study.
    Wassenaar MJ; Biermasz NR; van Duinen N; van der Klaauw AA; Pereira AM; Roelfsema F; Smit JW; Kroon HM; Kloppenburg M; Romijn JA
    Eur J Endocrinol; 2009 Mar; 160(3):357-65. PubMed ID: 19050166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
    Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients.
    Wassenaar MJ; Biermasz NR; Kloppenburg M; van der Klaauw AA; Tiemensma J; Smit JW; Pereira AM; Roelfsema F; Kroon HM; Romijn JA
    Growth Horm IGF Res; 2010 Jun; 20(3):226-33. PubMed ID: 20194043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects.
    Colao A; Marzullo P; Spiezia S; Ferone D; Giaccio A; Cerbone G; Pivonello R; Di Somma C; Lombardi G
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1986-91. PubMed ID: 10372698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of acromegalic arthropathy in long-term controlled acromegaly patients: 9 years of longitudinal follow-up.
    Pelsma ICM; Biermasz NR; van Furth WR; Pereira AM; Kroon HM; Kloppenburg M; Claessen KMJA
    J Clin Endocrinol Metab; 2021 Jan; 106(1):188-200. PubMed ID: 33099640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
    Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
    Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study.
    Claessen KM; Ramautar SR; Pereira AM; Smit JW; Roelfsema F; Romijn JA; Kroon HM; Kloppenburg M; Biermasz NR
    Eur J Endocrinol; 2012 Aug; 167(2):235-44. PubMed ID: 22645199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
    Kaltsas GA; Isidori AM; Florakis D; Trainer PJ; Camacho-Hubner C; Afshar F; Sabin I; Jenkins JP; Chew SL; Monson JP; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1645-52. PubMed ID: 11297598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
    Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
    Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GH and mortality in acromegaly.
    Sheppard MC
    J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance.
    Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Della Morte AM; Pivonello R; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1551-7. PubMed ID: 11297582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.